Form 4: AXIM Biotechnologies CFO Acquires Convertible Note

Robert Malasek, CFO of AXIM Biotechnologies, acquired a convertible note worth $53,500, which can be converted into 2,675,000 shares of common stock at $0.02 per share.

Summary

• Robert Malasek, the Chief Financial Officer of AXIM Biotechnologies, Inc., filed a Form 4 indicating a change in beneficial ownership.
• On March 15, 2024, Malasek acquired a convertible note with a face value of $53,500.
• This note is convertible into 2,675,000 shares of AXIM Biotechnologies' common stock at a conversion price of $0.02 per share.
• Following this transaction, Malasek directly owns 3,475,000 shares of common stock, including those obtainable from the convertible note.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a transaction by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track changes in ownership and potential alignment of interests.

Stakeholder Impact

• The acquisition of a convertible note by the CFO could signal confidence in the company's future prospects to shareholders.
• The transaction could potentially dilute existing shareholders if the note is converted into common stock.

Key Dates

Keywords

Convertible Note, Form 4, Beneficial Ownership, AXIM Biotechnologies, Robert Malasek, CFO, Securities